Citations

Showing 10 of 108083 citations.

American College of Surgeons Children’s Surgery Verification Quality Improvement Program: What Anesthesiologists Need to Know Now
Houck, Constance S. , Deshpande, Jayant K., Flick, Randall P., Peterson, Melissa Brooks

Mayo Clinic

Anesthesia & Analgesia | December 13, 2017 | Volume: 126 | Issue: 5 | Pages: 1624-1632

10.1213/ane.0000000000002672 | PMID 29239957 Get It

A task force of pediatric surgical specialists with the support of The American College of Surgeons recently launched a verification program for pediatric surgery, the Children’s Surgery Verification quality improvement program, with the goal of improving pediatric surgical, procedural, and perioperative care. Included in this program are specific standards for the delivery of pediatric anesthesia care across a variety of practice settings. We review the background, available evidence, requirements for verification, and verification process and its implications for the practice of pediatric anesthesia across the country. In addition, we have included a special roundtable interview of 3 recently Children’s Surgery Verification–verified program directors to provide an up-to-date real-world perspective of this children’s surgery quality improvement program.
Data Resource Profile: Expansion of the Rochester Epidemiology Project medical records-linkage system (E-REP)
Rocca, Walter A. , Brue, Scott M., Bock-Goodner, Cynthia M., Chamberlain, Alanna M. , Wilson, Patrick M. , Sauver, Jennifer L. St. , Finney Rutten, Lila J, St Sauver, Jennifer L , Chamberlain, Alanna M , Grossardt, Brandon R. , Rutten, Lila J. Finney

Mayo Clinic

International Journal of Epidemiology | December 13, 2017 | Volume: 47 | Issue: 2 | Pages: 368-368j

10.1093/ije/dyx268 | PMID 29346555 Get It

Effects of force fields on the conformational and dynamic properties of amyloid β(1‐40) dimer explored by replica exchange molecular dynamics simulations
Watts, Charles R. , Gregory, Andrew , Frisbie, Cole P., Lovas, Sándor , Frisbie, Cole, Gregory, Andrew

Mayo Clinic

Proteins: Structure, Function, and Bioinformatics | December 13, 2017 | Volume: 86 | Issue: 3 | Pages: 279-300

10.1002/prot.25439 | PMID 29235155 Get It

Abstract The conformational space and structural ensembles of amyloid beta (Aβ) peptides and their oligomers in solution are inherently disordered and proven to be challenging to study. Optimum force field selection for molecular dynamics (MD) simulations and the biophysical relevance of results are still unknown. We compared the conformational space of the Aβ(1‐40) dimers by 300 ns replica exchange MD simulations at physiological temperature (310 K) using: the AMBER‐ff99sb‐ILDN, AMBER‐ff99sb*‐ILDN, AMBER‐ff99sb‐NMR, and CHARMM22* force fields. Statistical comparisons of simulation results to experimental data and previously published simulations utilizing the CHARMM22* and CHARMM36 force fields were performed. All force fields yield sampled ensembles of conformations with collision cross sectional areas for the dimer that are statistically significantly larger than experimental results. All force fields, with the exception of AMBER‐ff99sb‐ILDN (8.8 ± 6.4%) and CHARMM36 (2.7 ± 4.2%), tend to overestimate the α‐helical content compared to experimental CD (5.3 ± 5.2%). Using the AMBER‐ff99sb‐NMR force field resulted in the greatest degree of variance (41.3 ± 12.9%). Except for the AMBER‐ff99sb‐NMR force field, the others tended to under estimate the expected amount of β‐sheet and over estimate the amount of turn/bend/random coil conformations. All force fields, with the exception AMBER‐ff99sb‐NMR, reproduce a theoretically expected β‐sheet‐turn‐β‐sheet conformational motif, however, only the CHARMM22* and CHARMM36 force fields yield results compatible with collapse of the central and C‐terminal hydrophobic cores from residues 17‐21 and 30‐36. Although analyses of essential subspace sampling showed only minor variations between force fields, secondary structures of lowest energy conformers are different.
Improving Preoperative Medication Instructions and Patient Adherence: A Collaborative, Hospital-Based Quality Improvement Project
Renew, Jr, Bolton, Je, Alvarado, Jm Irizarry, Ruyter, ML De

Mayo Clinic

Journal of Perioperative Practice | December 13, 2017 | Volume: 25 | Issue: 3 | Pages: 40-45

10.1177/175045891502500303 | PMID 26016281 Get It

The goal of this project was to improve preoperative medication instructions. After baseline data were collected prospectively through standardised patient surveys, preoperative care providers were educated to convey clear, appropriate preoperative medication instructions. After the education period, patient surveys were again completed to assess improvement. Hospital-wide education effectively increased the percentage of medications with written, colour-coded, and medically appropriate instructions. Patients found the instructions clearer and easier to follow.
Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome
Finch, NiCole A., Gavrilova, Ralitza H. , Fields, Julie A. , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Dheel, Christina, Gearhart, Debra, Rademakers, Rosa , Dheel, Christina M, Gearhart, Debra J, Jack, Clifford R , Botha, Hugo , Machulda, Mary M. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Neurology Genetics | December 13, 2017 | Volume: 3 | Issue: 6 | Pages: No page available

10.1212/nxg.0000000000000201 | PMID 29264393 Get It

ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association
Alfugham, Nora, Gadoth, Avi , Lennon, Vanda A. , Komorowski, Lars , Scharf, Madeleine, Hinson, Shannon R., McKeon, Andrew , Pittock, Sean J. , Hinson, Shannon, Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | December 13, 2017 | Volume: 5 | Issue: 1 | Pages: No page available

10.1212/nxi.0000000000000418 | PMID 29379822 Get It

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer
Kawakami, Hisato , Liu, Weizhen , Zeng, Xiangyu , Strebhardt, Klaus , Tao, Kaixiong , Huang, Shengbing, Zhang, Peng , Sinicrope, Frank A. , Zeng, Xiangyu

Mayo Clinic

Molecular Cancer Research | December 13, 2017 | Volume: 16 | Issue: 3 | Pages: 378-389

10.1158/1541-7786.mcr-17-0404 | PMID 29233910 Get It

Abstract The BRAFV600E mutation occurs in approximately 8% of human colorectal cancers and is associated with therapeutic resistance that is due, in part, to reactivation of MEK/ERK signaling cascade. Recently, pathway analysis identified cyclin-dependent kinase 1 (CDK1) upregulation in a subset of human BRAFV600E colorectal cancers. Therefore, it was determined whether CDK1 antagonism enhances the efficacy of MEK inhibition in BRAFV600E colorectal cancer cells. BRAFV600E colorectal cancer cell lines expressing CDK1 were sensitized to apoptosis upon siRNA knockdown or small-molecule inhibition with RO-3306 (CDK1 inhibitor) or dinaciclib (CDK1, 2, 5, 9 inhibitors). Combination of RO-3306 or dinaciclib with cobimetinib (MEK inhibitor) cooperatively enhanced apoptosis and reduced clonogenic survival versus monotherapy. Cells isogenic or ectopic for BRAFV600E displayed resistance to CDK1 inhibitors, as did cells with ectopic expression of constitutively active MEK. CDK1 inhibitors induced a CASP8-dependent apoptosis shown by caspase-8 restoration in deficient NB7 cells that enhanced dinaciclib-induced CASP3 cleavage. CDK inhibitors suppressed pro-CASP8 phosphorylation at S387, as shown by drug withdrawal, which restored p-S387 and increased mitosis. In a colorectal cancer xenograft model, dinaciclib plus cobimetinib produced significantly greater tumor growth inhibition in association with a caspase-dependent apoptosis versus either drug alone. The Cancer Genome Atlas (TCGA) transcriptomic dataset revealed overexpression of CDK1 in human colorectal cancers versus normal colon. Together, these data establish CDK1 as a novel mediator of apoptosis resistance in BRAFV600E colorectal cancers whose combined targeting with a MEK/ERK inhibitor represents an effective therapeutic strategy. Implications: CDK1 is a novel mediator of apoptosis resistance in BRAFV600E colorectal cancers whose dual targeting with a MEK inhibitor may be therapeutically effective. Mol Cancer Res; 16(3); 378–89. ©2017 AACR.
Deep Venous Thrombosis and Bilateral Pulmonary Embolism Revealing Silent Celiac Disease: Case Report and Review of the Literature
Dumic, Igor , Martin, Scott, Salfiti, Nadim, Alempijević, Tamara , Watson, Robert, Alempijevic, Tamara , Dumic, Igor , Watson, Robert James

Mayo Clinic

Case Reports in Gastrointestinal Medicine | December 12, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-8

10.1155/2017/5236918 | PMID 29379656 Get It

Celiac disease (CD) is a systemic, chronic autoimmune disease that occurs in genetically predisposed individuals following dietary gluten exposure. CD can present with a wide range of gastrointestinal and extraintestinal manifestations and requires lifelong adherence to a gluten-free diet [GFD]. Venous thromboembolism (VTE) as a presentation of celiac disease is unusual and rarely reported. We present a case of a 46-year-old man who was admitted for shortness of breath and pleuritic chest pain and was found to have iron deficiency anemia, deep venous thrombosis, and bilateral pulmonary emboli (PE). After work-up for his anemia, the patient was diagnosed with CD. Comprehensive investigation for inherited or acquired prothrombotic disorders was negative. It is becoming increasingly recognized that CD is associated with an increased risk for VTE. PE, however, as a presentation of CD is exceedingly rare and to the best of our knowledge this is the third case report of such an occurrence and the only case report of a patient from North America. It is important to recognize that the first symptoms or signs of celiac disease might be extraintestinal. Furthermore, VTE as a presentation of CD is rare but life-threatening.
The role of serologic testing for Zika virus infection
Tran, Anthony , Theel, Elitza S.

Mayo Clinic

Reviews in Medical Microbiology | December 12, 2017 | Volume: 29 | Issue: 1 | Pages: 1-7

10.1097/mrm.0000000000000122 Get It

Direct detection of Zika virus (ZIKV) nucleic acid with nucleic acid tests is definitive laboratory evidence of infection. Initial studies suggest that the ZIKV viremic period is limited, leading the Centers for Disease Control and Prevention to recommend that nucleic acid tests be utilized only up to 14 days postsymptom onset in serum and urine. The host immune response to flaviviruses, including to ZIKV, primarily targets the viral envelope (E) protein, which has three main domains (ED I–III). Recent studies suggest that neutralizing antibodies against the EDIII domain are relatively specific and potentially able to discriminate between ZIKV and dengue virus, which share 29% amino acid homology at that region. Comparatively, neutralizing antibodies to EDI and EDII, with amino acid homologies of 35 and 51% between these two viruses, respectively, are highly cross-reactive and likely responsible for the nonspecific reactions observed in the respective serologic assays. The current article describes the humoral immune response to ZIKV, reviews serologic assays for detection of antibodies to ZIKV, discusses performance characteristics of commercially available tests, and summarizes the strengths and limitations of currently available serologic methods. Assays examined in the review include the Centers for Disease Control and Prevention Zika IgM antibody capture ELISA, InBios ZIKV Detect IgM Capture ELISA, DiaSorin, LIAISON XL Zika Capture IgM Assay, Euroimmun anti-ZIKV IgM ELISA, and plaque reduction neutralization tests. Despite the availability of multiple diagnostic tests, there remains a need for modified and novel testing strategies, including the potential use of multiple enzyme immunoassays either in parallel or sequentially and IgG in addition to IgM determination.
Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels
Wyatt, Kirk D. , Cooper, J. R. , Scott, Katherine, Broomall, Eileen, Altaf, Sadaf , Hogan, Marie C. , Rodriguez, Vilmarie , Khan, Shakila P. , Khan, Shakila, Cooper, Jeffrey, Hogan, Marie C

Mayo Clinic

Journal of Pediatric Hematology/Oncology | December 12, 2017 | Volume: 40 | Issue: 2 | Pages: 152-155

10.1097/mph.0000000000001058 | PMID 29240024 Get It

High-dose methotrexate has been a treatment for osteosarcoma; however, its nephrotoxic effects are considerable. Carboxypeptidase-G2 (glucarpidase) was approved by the US Food and Drug Administration in 2012 for treatment of toxic methotrexate levels. We report our experience using glucarpidase under compassionate use before Food and Drug Administration approval in 2 patients who had delayed methotrexate clearance and prolonged kidney injury despite glucarpidase administration. Our results show that patients with methotrexate toxicity may require repeated doses of glucarpidase in addition to supportive measures, such as dialysis.